Lemtrada
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.lemtrada.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Lemtrada
Lemtrada is approved in more than 40 countries, with additional marketing applications under review. Lemtrada is supported by a comprehensive and extensive clinical development program that involved nearly 1,500 patients worldwide and 5,400 patient-years of follow-up. Alemtuzumab is a monoclonal antibody that targets CD52, a protein abundant on T and B cells. Circulating T and B cells are thought to be responsible for the damaging inflammatory process in MS. Although the exact mechanism of action for alemtuzumab is unknown, it is presumed to deplete circulating T and B lymphocytes after each treatment course. Lymphocyte counts then increase over time with a reconstitution of the lymphocyte population that varies for the different lymphocyte subtypes. Genzyme holds the worldwide rights to alemtuzumab and has responsibility for its development and commercialization in multiple sclerosis. Bayer Healthcare receives contingent payments based on global sales revenue.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lemtrada your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Lemtrada is spiking on competitors!
Click to see if Lemtrada had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Lemtrada
Product Launch: Get notified when Lemtrada launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Lemtrada has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Lemtrada has new funding data
Earning: See what the market has to say on Lemtrada recently announced quarterly report
Lemtrada, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Lemtrada
Find more new buyers
Compare Similar Companies to Lemtrada
Compare insights from companies similar to Lemtrada, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Company Profile Activity
Activity Insights
Lemtrada is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lemtrada is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lemtrada.
Lemtrada Tech Stack
A closer look at the technologies used by Lemtrada
See more technologies
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lemtrada
Sign Up For FreeTo access detailed company insights
Lemtrada is approved in more than 40 countries, with additional marketing applications under review. Lemtrada is supported by a comprehensive and extensive clinical development program that involved nearly 1,500 patients worldwide and 5,400 patient-years of follow-up. Alemtuzumab is a monoclonal antibody that targets CD52, a protein abundant on T a... Read More
